

Panacea introduces a novel anti-allergy drug

07 July 2005 | News



Panacea Biotec has launched Ralif (rupatadine 10 mg) a novel anti-allergy drug for the management of diseases with allergic inflammatory conditions, such as seasonal and perennial Allergic Rhinitis. According to Rajesh Jain, joint managing director, Panacea Biotec, "The introduction of new and novel therapies is an integral part of our continuous effort to provide innovative yet affordable drug therapies to the ailing humanity. Ralif has a dual mechanism of action which provides better relief from both allergy and associated inflammation whereas currently available molecules for Allergic Rhinitis have antihistaminic property only." Panacea Biotec is one of the leading health management companies in India involved in the research, production and marketing of pharmaceuticals, vaccines and biotechnology products.